跳至主要内容
临床试验/NCT05908097
NCT05908097
已完成
早期 1 期

Enhancing Prospective Thinking in Early Recovery

Indiana University3 个研究点 分布在 1 个国家目标入组 104 人2023年4月4日

概览

阶段
早期 1 期
干预措施
Virtual Reality Empty Park
疾病 / 适应症
Opioid Use
发起方
Indiana University
入组人数
104
试验地点
3
主要终点
Future Self-Identification
状态
已完成
最后更新
3个月前

概览

简要总结

The goal of this clinical trial is to demonstrate the commercial potential for a novel virtual reality (VR) intervention in preparation for Phase II development. This clinical trial will test the VR intervention for efficacy in reducing opioid use, increasing abstinence, and other self-reported and behavioral focus on future outcomes in individuals in early recovery from opioid use disorder.

  • Will the VR group, compared to the control group, have a lower number of opioid use days?
  • Will the VR group, compared to the control group, have longer periods of abstinence at the 30-day follow-up?
  • Will the VR group, compared to the control group, have significantly increased opioid abstinence rates?
  • Will the VR group, compared to baseline and the control group, show increased future self-identification post-VR intervention?
  • Will the VR group, compared to baseline and the control group, show increased future orientation post-VR intervention?
  • Will the VR group, compared to baseline and the control group, show an increased preference for delayed rewards in a laboratory delay discounting task post-VR intervention?
  • Will the VR group, compared to baseline and the control group, exceed in behavioral effects (i.e., future self-identification, future orientation, and increased preference for delayed rewards) at the 30-day follow-up?

Researchers will compare the VR test group and the control group to see if there are differences in the results for the questions outlined above.

注册库
clinicaltrials.gov
开始日期
2023年4月4日
结束日期
2025年9月14日
最后更新
3个月前
研究类型
Interventional
研究设计
Parallel
性别
All

研究者

责任方
Principal Investigator
主要研究者

Brandon G. Oberlin, PhD

Assistant Professor

Indiana University

入排标准

入选标准

  • Abstinence between ≥14 days and ≤ 1 year
  • 18-60 years old
  • Verbal endorsement of commitment to recovery
  • Outpatient
  • Psychotropic drugs for SUD-comorbidity
  • Mu-Opioid drugs
  • Drug/alcohol abstinence ≥ 24 hours at the time of the study day visit
  • English comprehension

排除标准

  • Unstable medical disorders
  • Outside the age range of 18-60
  • Habitual drug use
  • Smell/taste disorders
  • Unstable psychiatric conditions
  • Extravagant/elaborate face tattoos

研究组 & 干预措施

Sham VR (Control)

Participants in this arm will receive the following interventions: Sham VR plus Treatment As Usual (Empty Virtual Reality Park)

干预措施: Virtual Reality Empty Park

Virtual Reality

Participants in this arm will receive the following interventions: Virtual Reality Avatar VR plus Treatment As Usual (Intervention)

干预措施: Virtual Reality Avatar Intervention

Virtual Reality

Participants in this arm will receive the following interventions: Virtual Reality Avatar VR plus Treatment As Usual (Intervention)

干预措施: Virtual Reality Empty Park

结局指标

主要结局

Future Self-Identification

时间窗: Study Day Visit (Day 1); 30-day Follow-up Visit

The VR Avatar Experience will change future self-identification. Future self-identification and change between two time points will also be measured using a proprietary future-self-continuity assessment administered at Study Day Visit (Day 1), and again at the 30-Day Follow-up Visit.

Change in Overall Abstinence

时间窗: Study Day Visit (Day 1); 30-day Follow-up Visit.

The VR Avatar experience, compared to treatment as usual will change abstinence, measured using a timeline follow-back assessing for substances used from enrollment to study completion.

Increased Length of Abstinence

时间窗: Study Day Visit (Day 1); 30-day Follow-up Visit.

The VR Avatar experience will change the length of abstinence periods.

Future Time Orientation

时间窗: Study Day Visit (Day 1); 30-day Follow-up Visit.

The Virtual Reality Avatar experience will change orientation toward the future, which will be measured using the Zimbardo Time Perspective Inventory (ZTPI). The ZTPI contains five subscales, and items within each subscale are scored from 1, "very uncharacteristic," to 5, "very characteristic." The subscales are 1) Past-Negative--10 items, higher scores indicative of worse outcomes; 2) Present-Hedonistic--15 items, higher scores indicative of worse outcomes; 3) Future--10 items, higher scores indicative of better outcomes; 4) Past-Positive--9 items, higher scores indicative of better outcomes; and 5) Present-Fatalistic--9 items, higher scores indicative of worse outcomes. Subscales are combined into "future" and "present" categories, then totaled, with higher total scores indicative of worsened outcomes.

Reduced Use of Drug Using Days

时间窗: Study Day Visit; 30-day Follow-up Visit.

The VR Avatar experience will change drug using days.

Delayed Reward

时间窗: Study Day Visit (Day 1); 30-day Follow-up Visit.

The Virtual Reality Avatar experience will change preference for delayed rewards, which will be measured using a behavioral delay discounting task.

研究点 (3)

Loading locations...

相似试验